TAM
TERN

Tucker Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Tucker Asset Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,824
Closed -$24.7K – 1545
2023
Q2 		$24.7K Buy
+2,824
New +$32.9K 0.01% 372

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Tucker Asset Management's TERN Position: Q3 2023 in Review

Tucker Asset Management sold out of Terns Pharmaceuticals (TERN) in Q3 2023, closing a stake of 2,824 shares — an estimated $24.7K sold.

Tucker Asset Management first reported a position in TERN in Q2 2023 and held it in 1 quarter. The position peaked at $24.7K in Q2 2023. 93 funds tracked by Wall St. Rank hold TERN as of Q3 2023.

  • Tucker Asset Management reported no remaining Terns Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Tucker Asset Management sold 2,824 Terns Pharmaceuticals shares in Q3 2023, an estimated $24.7K.
  • Tucker Asset Management first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Tucker Asset Management's Terns Pharmaceuticals position peaked at $24.7K in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2023.

Based on Tucker Asset Management's 13F filing for Q3 2023, filed 4 Dec 2023.